Size : 50mg
Synonyms: NSC-301739, mitozantrone dihydrochloride, Mitoxantrone hydrochloride, Mitoxantrone 2HCl
| Description | Mitoxantrone dihydrochloride (NSC-301739) is the hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. It is a type II topoisomerase inhibitor. |
| Targets & IC50 | PKC:8.5 μM |
| In vitro | In a murine air pouch model of inflammation, methotrexate demonstrated an inhibitory concentration 50 (IC50) of 0.08 mg/kg per week. |
| In vivo | Methotrexate inhibits the de novo synthesis of purines and pyrimidines, the formation of polyamines, and the transmethylation reactions of DNA, RNA, phospholipids, and proteins. It suppresses the enzyme thymidylate synthase, leading to a deficiency of thymidylate inside cells, which ultimately results in antiproliferative cytotoxicity. Methotrexate enters cells either through active transport or facilitated diffusion and, once inside, polyglutamation inhibits dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate. |
| Synonyms | NSC-301739, mitozantrone dihydrochloride, Mitoxantrone hydrochloride, Mitoxantrone 2HCl |
| Cell Research | The human breast carcinoma cell lines MDA-MB-231 and MCF-7 are seeded in standard 96-well plates. One day after seeding, the culture medium is changed and replaced by medium containing different concentration of Mitoxantrone (10-5 to 5 μM) with or without DHA (30 μM) during 7 days. Viability of cells are measured as a whole by the tetrazolium salt assay[3]. |
| Molecular Weight | 517.4 |
| Formula | C22H30Cl2N4O6 |
| Cas No. | 70476-82-3 |
| Smiles | Cl.OCCNCCNc1c2C(=O)c3c(O)ccc(O)c3C(=O)c2c(NCCNCCO)cc1.Cl |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 38.8 mg/mL (74.99 mM), Sonication is recommended. H2O: 2.6 mg/mL (5.03 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.87 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
